Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared

Biotech Giants' SG&A Spending: A Decade of Growth

__timestampDynavax Technologies CorporationRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201417763000504755000
Thursday, January 1, 201522180000838526000
Friday, January 1, 2016372570001177697000
Sunday, January 1, 2017273670001320433000
Monday, January 1, 2018647700001556200000
Tuesday, January 1, 2019749860001834800000
Wednesday, January 1, 2020792560001346000000
Friday, January 1, 20211001560001824900000
Saturday, January 1, 20221314080002115900000
Sunday, January 1, 20231529460002631300000
Monday, January 1, 20242954400000
Loading chart...

Data in motion

SG&A Spending Patterns: A Tale of Two Biotechs

In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses.

Regeneron, a leader in the biotech industry, has consistently increased its SG&A spending, peaking at approximately $2.63 billion in 2023. This represents a staggering 420% increase from 2014, reflecting its aggressive expansion and market penetration strategies. In contrast, Dynavax's SG&A expenses grew by 760% over the same period, reaching around $153 million in 2023. This rapid increase highlights Dynavax's efforts to bolster its market presence and operational capabilities.

These spending patterns underscore the dynamic nature of the biotech sector, where strategic investments in SG&A can significantly influence a company's growth trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025